Across TCGA pan-cancer cohorts, KTI12 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated KTI12 data layer compared with 24 for mass-spec protein and 4 for mass-spec protein.
The strongest signal is observed in rectum adenocarcinoma (READ), where higher KTI12 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated KTI12 expression acts as an unfavorable survival marker.
READ and HNSC are the cancer types where KTI12 Mutation most reproducibly stratifies survival.